News | Hemodynamic Support Devices | November 02, 2015

Miracor’s PiCSO Impulse System Highlighted at TCT 2015

Device may offer improved heart attack outcomes as novel therapy for cardioprotected PCI in the future

Miracor, PiCSO Impulse System, TCT 2015, cardioprotection during PCI, acute myocardial infarction

November 2, 2015 — Miracor Medical Systems GmbH announced that its PiCSO system was highlighted during the 2015 Transcatheter Cardiovascular Therapeutics (TCT) conference in San as offering new hope for cardioprotection during percutaneous coronary intervention (PCI).

Myocardial salvage and the need for cardioprotection for patients with acute myocardial infarction (AMI) was a focus topic at the conference.

“Despite recent improvements in the treatment of AMI, including shortened door-to-balloon times and advanced pharmacological strategies, survival has plateaued, and novel strategies are needed to reduce infarct size and improve clinical outcomes, especially in patients with large ST-segment elevation MI (STEMI),” stated Gregg W. Stone, M.D., professor of medicine at Columbia University College and director of cardiovascular research and education at the New York-Presbyterian Hospital Center for Interventional Vascular Therapies, during a symposium on novel strategies in PCI with focus on PiCSO Therapy. “In recent years, many approaches to improve reperfusion success and myocardial salvage have failed. Emerging data suggests that the effective delivery of PICSO improves myocardial perfusion and may reduce infarct size in STEMI patients,” he continued.

PiCSO is applied during the stenting procedure, directly following flow restoration, and increases myocardial perfusion and microcirculation, thereby preventing so-called reperfusion injury — damage to the myocardium caused by the stenting procedure itself.

“Further therapies to protect my patients — especially during complex PCI procedures — are needed. At San Raffaele Hospital, we have used PiCSO in elective, as well as acute, high-risk PCI procedures and are pleased to see that PiCSO can be applied without significant interruption of our standard workflows and without increasing the risk for the patient,” said Antonio Colombo, M.D., director of cardiovascular interventions at San Raffaele Scientific Institute, Columbus Hospital in Milan, Italy. “Once the PiCSO catheter is placed in the coronary sinus and connected to the PiCSO console, therapy is applied fully automatically so that I can focus on the stenting procedure, knowing that the patient’s heart is protected by PiCSO.”

For more information: www.miracormedical.com


Related Content

News | TCT

Oct. 23, 2025 — At TCT 2025, the Cardiovascular Research Foundation (CRF) announced the 2025 SET-10 (Scientific ...

Home October 31, 2025
Home
News | TCT

Oct. 29, 2025 — FastWave Medical presented new first-in-human (FIH) and pre-clinical data for its Sola coronary laser ...

Home October 30, 2025
Home
News | TCT

Aug. 27, 2025 – The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical trials and science ...

Home August 28, 2025
Home
News | TCT

May 5, 2025 — The TCT Geoffrey O. Hartzler Master Operator Award will be presented to Kenneth Rosenfield, MD, MSc ...

Home May 05, 2025
Home
News | TCT

Oct. 11, 2024 – As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine ...

Home October 16, 2024
Home
News | TCT

November 9, 2023 — Medinbox, a global provider of video integrated collaboration systems for interventional rooms and ...

Home November 09, 2023
Home
News | TCT

October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has ...

Home October 30, 2023
Home
News | TCT

October 26, 2023 — The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued ...

Home October 26, 2023
Home
News | TCT

October 26, 2023 — A new study presented at TCT 2023 revealed inequities in access to mechanical circulatory support in ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical ...

Home October 25, 2023
Home
Subscribe Now